Credit Suisse Adds New Stocks to Buy to Top Picks List

Photo of Lee Jackson
By Lee Jackson Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

The higher the market goes, the harder it is for investors to know what to do. One good strategy is to always buy stocks that are the highest conviction picks at a Wall Street firm. These ideas are given to the top institutional and high net worth clients, so the firms generally put their best research foot forward. In a new report from, Credit Suisse, they add some new stocks to the firm’s prestigious Top Picks list.

The Credit Suisse Top Picks list has 148 stocks, which represents just about 17% of the total stocks they cover. We looked for the new stocks added as number one ideas, as each analyst is allowed to enter three top picks. Here are four of the new number one top picks added to the Credit Suisse list: Aramark Inc. (NASDAQ: ARMK), Biogen Inc. (NASDAQ: BIIB), Hewlett-Packard Corp. (NYSE: HPQ) and McKesson Corp. (NYSE: MCK).

Aramark

This top industrial stock provides food, facilities and uniform services to education, health care, business and industry, sports, leisure and corrections clients primarily in North America. The company also offers managed services, including dining, catering, food service management, convenience-oriented retail operations, grounds and facilities maintenance, custodial, energy and construction management, and capital project management.

The Credit Suisse analysts see a deleveraging and capital return story that could start next year. They also think the company can generate $1.2 billion in cash over the next three years, which they see as providing the impetus to drive the stock higher.

Aramark investors are paid a 1.11% dividend. The Credit Suisse price target for the stock is $37, and Thomson/First Call consensus price target is $35.57. Shares closed Tuesday at $31.05.

ALSO READ: Cloud Networking Stocks to Buy as Sector Stays Red Hot

Biogen

Biogen is a top biotech stock that jumps onto the list at Credit Suisse. The analysts cite the fact that greater investor appreciation of the company’s outstanding pipeline can drive the biotech giant’s shares higher. They also note that the recent slowdown in Tecfidera sales has long since been priced into the stock.

The stock jumped in March after the company’s experimental drug for Alzheimer’s disease exceeded already high expectations in an early study. The medicine, known as BIIB037, or aducanumab, showed both reductions in levels of the amyloid plaques in the brain associated with Alzheimer’s and a significant slowing of the disease’s hallmark cognitive declines.

The Credit Suisse price target for this large cap leader is posted at a massive $500, and the Thomson/First Call consensus is $483.84. Shares closed Tuesday at $385.80.

Hewlett-Packard

This old-school tech stock has been sold off hard as investors feel that the PC slowdown in sales could continue to hurt earnings. In fact, the stock is down a whopping 20% year to date and trades at a very low 8.9 times 2015 estimated earnings. Some Wall Street analysts feel that weak PC demand could continue to negatively impact revenue and free-cash-flow at the company. The recent decline in the stock may represent investors already discounting a weak first quarter. HP does a large 65% of sales to foreign accounts, and the dollar could be topping out after a long run.

ALSO READ: 4 ETFs to Buy to Protect Against Huge Market Losses

The server business is where many top analysts on Wall Street are bullish, and by adding in the firm’s very solid printer business, investors may be well advised to look at this stock at current lower trading levels. The Credit Suisse team views the stock as undervalued, and it should beat very conservative guidance.

HP investors are paid a 2.2% dividend. Credit Suisse has a very solid $45 price target. The consensus target is $40.40. Shares closed Tuesday at $33.16. The company reports earnings in late May.

McKesson

This company is the largest U.S. drug distributor and is also a health care services and information technology company dedicated to making the business of health care run better. It partners with payers, hospitals, physician offices, pharmacies, pharmaceutical companies and others across the spectrum of care to build healthier organizations that deliver better care to patients in every setting. McKesson helps its customers improve their financial, operational and clinical performance with solutions that include pharmaceutical and medical-surgical supply management, health care information technology, and business and clinical services.

The Credit Suisse team sees an overall solid fundamental backdrop for the company, in addition to seeing positive accretion from the purchase of Celesio, a European health care and pharmaceutical company.

McKesson investors are paid a small 0.45% dividend. The Credit Suisse price target is posted at $255, and the consensus stands at $247.06. Shares closed most recently at $222.78.

ALSO READ: 4 Oil Service Stocks to Buy as Rig Count Continues to Plunge

These top pick additions all make good sense for long-term growth investors. They are large cap leaders that should hold up better than momentum stocks in the event of a sell-off.

Photo of Lee Jackson
About the Author Lee Jackson →

Lee Jackson has covered Wall Street analysts' equity and debt research and equity strategy daily for 24/7 Wall St. since 2012. His broad and diverse career, which included a stint as the creative services director at the NBC affiliate in Austin, Texas, gives him unique insight into the financial industry and world.

Lee Jackson's journey in the financial industry spans over 30 years, with nearly two decades as an institutional equity salesperson at Bear Stearns, Lehman Brothers, and Morgan Stanley. His career was marked by his presence on the sell side during pivotal Wall Street events, from the dot.com rise and bubble to the Long Term Capital Management debacle, 9/11, and the Great Recession of 2008. This is a testament to his resilience and adaptability in the face of market volatility.

Lee Jackson’s practical financial industry experience, acquired from a career at some of the biggest banks and brokerage firms, is complemented by a lifetime of writing on various platforms. This unique combination allows him to shed light on the intricacies and workings of Wall Street in a way that only someone with deep insider experience and knowledge can. Moreover, his extensive network across Wall Street continues to provide direct access for him and 24/7 Wall St., a privilege few firms enjoy.

Since 2012, Jackson’s work for 24/7 Wall St. has been featured in Barron’s, Yahoo Finance, MarketWatch, Business Insider, TradingView, Real Money, The Street, Seeking Alpha, Benzinga, and other media outlets. He attended the prestigious Cranbrook Schools in Bloomfield Hills, Michigan, and has a degree in broadcasting from the Specs Howard School of Media Arts.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618